Allergy Therapeutics PLC Directorate Change (2838W)
February 08 2017 - 2:00AM
UK Regulatory
TIDMAGY
RNS Number : 2838W
Allergy Therapeutics PLC
08 February 2017
8 February 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the 'Company")
Directorate Change
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
the appointment of Mr Jeff Barton to the Company's Board as a
Non-Executive Director, nominated by Abbott Laboratories, Inc.
("Abbot", NYSE: ABT) in replacement of Mr Jean-Yves Pavee who
retires from the Board, both effective after close of business 7
February 2017.
Jeff Barton currently serves as Vice President, Licensing and
Acquisitions, at Abbott. During his time in this role, Abbott has
executed several strategically important transactions including the
acquisition of St. Jude Medical, CFR Pharmaceuticals and Veropharm.
He has served Abbott since joining in 1990 in the Financial
Development Training program, and during his career has held a
variety of financial management positions across Abbott's
businesses, including in Diagnostics, Nutrition and
Pharmaceuticals. He previously served as Divisional Vice President
and Controller for Abbott's North American Nutrition Business and
as Area Finance Director for its Asian, African, and Middle Eastern
Pharmaceutical unit. Mr Barton holds a degree in accounting from
Indiana University, and a Masters of Management from the
Northwestern University Kellogg Graduate School of Management.
Peter Jensen, Chairman of Allergy Therapeutics, commented: "We
are pleased to welcome Jeff to the Board. He brings extensive
commercial experience, particularly in the United States, which
will be valuable to our Company as we continue to execute our
global strategy. We also wish to take this opportunity to thank
Jean-Yves for his contribution and support to Allergy Therapeutics
since 2014."
Jeffery Glen Barton, age 48, has no current or prior
directorships in the past five years. Allergy Therapeutics confirms
that there are no further disclosures to be made in relation to
Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for
Companies.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focused on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.495 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUGUBCPUPMPGM
(END) Dow Jones Newswires
February 08, 2017 02:00 ET (07:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024